Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on X about a recent paper by Praneeth Reddy Keesari et al. published in Current Hematologic Malignancy Reports:

“Myeloma Drug Prices (from the expensive to the cheapest!)

Cilta-Cel $507,000
Ide-Cel $503,000
Elrantamab $486,000/yr
Selinexor $442,000/yr
Talquetamab $372,000/yr
Pomalidomide $300,000/yr
Lenalidomide $240,000/yr
Teclistimab $235,000/yr
Carfilzomib $173,000/yr
Daratumumab $165,000/yr
Ixazomib $136,000/yr
Cyclophosphamide $8,000/yr
Bortezomib $2,000/yr
Dexamethasone $570/yr.”

“Navigating the Economic Burden of Multiple Myeloma: Insights into Cost‑efectiveness of CAR‑T and Bispecifc Antibody Therapies”

Authors: Praneeth Reddy Keesari, Diana Samuels, Charan Thej Reddy Vegivinti, Yashwitha Sai Pulakurthi, Revathi Kudithi, Meekoo Dhar, Murali Janakiram.

Al-Ola Abdallah: Myeloma Drug Prices

More posts featuring Al-Ola Abdallah.